196 related articles for article (PubMed ID: 23358899)
1. Impact of frequent hemodialysis on anemia management: results from the Frequent Hemodialysis Network (FHN) Trials.
Ornt DB; Larive B; Rastogi A; Rashid M; Daugirdas JT; Hernandez A; Kurella Tamura M; Suri RS; Levin NW; Kliger AS;
Nephrol Dial Transplant; 2013 Jul; 28(7):1888-98. PubMed ID: 23358899
[TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
3. Management of anemia with quotidian hemodialysis.
Rao M; Muirhead N; Klarenbach S; Moist L; Lindsay RM
Am J Kidney Dis; 2003 Jul; 42(1 Suppl):18-23. PubMed ID: 12830439
[TBL] [Abstract][Full Text] [Related]
4. The effect of increased frequency of hemodialysis on vitamin C concentrations: an ancillary study of the randomized Frequent Hemodialysis Network (FHN) daily trial.
Raimann JG; Abbas SR; Liu L; Larive B; Beck G; Kotanko P; Levin NW; Handelman G;
BMC Nephrol; 2019 May; 20(1):179. PubMed ID: 31101018
[TBL] [Abstract][Full Text] [Related]
5. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
[TBL] [Abstract][Full Text] [Related]
6. Effect of frequency of intravenous iron administration on hemoglobin variability in maintenance hemodialysis patients.
Wan L; Zhang D
Int Urol Nephrol; 2018 Aug; 50(8):1511-1518. PubMed ID: 29946818
[TBL] [Abstract][Full Text] [Related]
7. [The use of erythropoietin beta, two to three times per week, once per week and once every other week: meta-analysis of two clinical trials].
Pljesa S
Med Pregl; 2007; 60(3-4):123-7. PubMed ID: 17853722
[TBL] [Abstract][Full Text] [Related]
8. Anemia in hemodialysis patients: variables affecting this outcome predictor.
Madore F; Lowrie EG; Brugnara C; Lew NL; Lazarus JM; Bridges K; Owen WF
J Am Soc Nephrol; 1997 Dec; 8(12):1921-9. PubMed ID: 9402095
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
10. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
11. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
12. Effects of frequent hemodialysis on blood pressure: Results from the randomized frequent hemodialysis network trials.
Kotanko P; Garg AX; Depner T; Pierratos A; Chan CT; Levin NW; Greene T; Larive B; Beck GJ; Gassman J; Kliger AS; Stokes JB;
Hemodial Int; 2015 Jul; 19(3):386-401. PubMed ID: 25560227
[TBL] [Abstract][Full Text] [Related]
13. Hemoglobin level variability in hemodialysis patients treated with epoetin-β during 1 year.
Kessler M; Landais P; Bataille P; Yver L; Koné S; Kraemer S; Brillet G; Canivet E
Clin Nephrol; 2011 Sep; 76(3):210-7. PubMed ID: 21888858
[TBL] [Abstract][Full Text] [Related]
14. Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
Bae MN; Kim SH; Kim YO; Jin DC; Song HC; Choi EJ; Kim YL; Kim YS; Kang SW; Kim NH; Yang CW; Kim YK
PLoS One; 2015; 10(11):e0143348. PubMed ID: 26588085
[TBL] [Abstract][Full Text] [Related]
15. Indole 3-acetic acid, indoxyl sulfate and paracresyl-sulfate do not influence anemia parameters in hemodialysis patients.
Bataille S; Pelletier M; Sallée M; Berland Y; McKay N; Duval A; Gentile S; Mouelhi Y; Brunet P; Burtey S
BMC Nephrol; 2017 Jul; 18(1):251. PubMed ID: 28747155
[TBL] [Abstract][Full Text] [Related]
16. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.
Coritsidis GN; Maglinte GA; Acharya A; Saxena A; Chang CL; Hill J; Gitlin M; Lafayette RA
Clin Ther; 2014 Mar; 36(3):408-18. PubMed ID: 24582713
[TBL] [Abstract][Full Text] [Related]
17. Multifactorial analysis of renal anemia-associated substandard hemoglobin levels and prevalence of anemia in patients on maintenance hemodialysis in Liaoning Province: a cross-sectional study.
Yin S; Du Y; Guo Y; Guo G; Sun D; Yao L
Ann Palliat Med; 2022 Dec; 11(12):3743-3754. PubMed ID: 36635999
[TBL] [Abstract][Full Text] [Related]
18. Chapter 8 Haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2010: national and centre-specific analyses.
Webb L; Gilg J; Wilkie M
Nephron Clin Pract; 2012; 120 Suppl 1():c145-74. PubMed ID: 22964566
[TBL] [Abstract][Full Text] [Related]
19. Impact of nocturnal home hemodialysis on anemia management in patients with end-stage renal disease.
Schwartz DI; Pierratos A; Richardson RM; Fenton SS; Chan CT
Clin Nephrol; 2005 Mar; 63(3):202-8. PubMed ID: 15786821
[TBL] [Abstract][Full Text] [Related]
20. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
